Consensus Black Diamond Therapeutics, Inc. OTC Markets

Stocks

BDTX

US09203E1055

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-05	Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Index	CI

d71273bd5e17bc19b82949ef0b.GSb6zaCRqUzz2XU4IgZsZzpy7Q2dqA3KzYEhVsFn-yw.fVSKl8Hl0Qix7E15ckMABGNHmW6wx3qrv8RzEYgqw29dYrSH8ajfdL6INA~d7ab3524fcef7c5f5a49b01cf52fbf51

Analysts' recommendations: Black Diamond Therapeutics, Inc.

03-17	Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating	MT
25-08-07	Black Diamond Therapeutics Q2 net loss narrows as costs drop	RE
25-03-07	Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating	MT
24-07-31	Raymond James Initiates Black Diamond Therapeutics at Outperform	MT
24-05-16	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT
24-04-08	Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	MT
23-07-14	Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	MT
23-06-30	Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	MT
23-06-28	HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11	MT
23-06-27	Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3	MT
22-05-12	Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating	MT
22-04-01	Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating	MT
22-03-29	Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22	MT
22-03-22	HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy	MT
22-03-18	Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating	MT
21-09-30	Black Diamond Therapeutics : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target	MT
21-08-17	Black Diamond Therapeutics : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating	MT
21-08-17	Black Diamond Therapeutics : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating	MT
21-05-21	Black Diamond Therapeutics : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48	MT
21-03-29	Black Diamond Therapeutics : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48	MT
21-03-26	Black Diamond Therapeutics : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating	MT
21-01-07	Black Diamond Therapeutics : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target	MT
20-11-24	Black Diamond Therapeutics : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+23.69%
	ARGENX SE					+18.14%
	INSMED INCORPORATED					+54.69%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.66%
	BIONTECH SE					+23.2%
	GENMAB A/S					+17.29%
	PHARMAESSENTIA CORPORATION					+9.16%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.94%
	SUMMIT THERAPEUTICS INC.					+66.2%
	Average					+29.89%
	Weighted average by Cap.					+26.94%